Attached files

file filename
EX-31.2 - CERTIFICATION OF THE CAO PURSUANT TO SECTION 302 - VERMILLION, INC.d360757dex312.htm
EX-31.1 - CERTIFICATION OF THE CEO PURSUANT TO SECTION 302 - VERMILLION, INC.d360757dex311.htm
EX-32.1 - CERTIFICATION OF THE CEO AND CAO, PURSUANT TO 18 U.S.C. SECTION 1350 - VERMILLION, INC.d360757dex321.htm
EX-10.51 - SETTLEMENT AGREEMENT AND RELEASE - VERMILLION, INC.d360757dex1051.htm
Table of Contents

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 10-K/A

(Amendment No. 2)

 

x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Fiscal Year Ended December 31, 2011.

 

¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from             to             

Commission File Number: 001-34810

 

 

Vermillion, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware   33-0595156

(State or other jurisdiction of

incorporation or organization)

 

(I.R.S. Employer

Identification No.)

12117 Bee Caves Road, Building Three, Suite 100,

Austin, Texas

  78738
(Address of principal executive offices)   (Zip Code)

Registrant’s telephone number, including area code: (512) 519-0400

 

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class to be so registered

 

Name of each exchange on which registered

Common Stock, par value $0.001 per share   The NASDAQ Stock Market, LLC

Securities registered pursuant to Section 12(g) of the Act: None

 

 

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.    Yes  ¨    No  x

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.    Yes  ¨    No  x

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  x    No  ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Date File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    Yes  x    No  ¨

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K  x.

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

 

Large accelerated filer   ¨    Accelerated filer   ¨
Non—Accelerated filer   ¨    Smaller reporting company   x

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).    Yes  ¨    No  x

Indicate by check mark whether the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court.    Yes  x    No  ¨

The aggregate market value of voting common stock held by non-affiliates of the Registrant is $45,564,126 and is based upon the last sales price as quoted on The NASDAQ Global Market as of June 30, 2011.

As of May 30, 2012, the Registrant had 14,936,913 shares of common stock, par value $0.001 per share, outstanding.

DOCUMENTS INCORPORATED BY REFERENCE:

None.

 

 

 


Table of Contents

VERMILLION, INC.

FORM 10-K/A

For the Fiscal Year Ended December 31, 2011

Table of Contents

 

     Page No.  

EXPLANATORY NOTE

     2   

PART IV

     3   

ITEM 15.     EXHIBITS AND FINANCIAL STATEMENT SCHEDULES

     3   

SIGNATURES

  

INDEX TO EXHIBITS

  

 

1


Table of Contents

EXPLANATORY NOTE

Vermillion, Inc. (the “Company”) is filing this Amendment No. 2 to the Company’s Annual Report on Form 10-K/A (this “Amendment No. 2”) to amend the Company’s Annual Report on Form 10-K for the year ended December 31, 2011 filed with the Securities and Exchange Commission (the “Commission”) on March 27, 2012 (the “Annual Report”), as amended by the Company’s Amendment No. 1 to Annual Report on Form 10-K/A, filed with the Commission on April 27, 2012 (“Amendment No. 1”). The Company is filing this Amendment No. 2 in response to communications with the Commission in connection with a request for confidential treatment under Rule 24b-2 promulgated under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), with respect to Exhibit 10.51 (the “Exhibit”) originally filed with the Annual Report. The sole purpose of this Amendment No. 2 is to file a revised version of the Exhibit in order to disclose certain information for which confidential treatment had been previously requested and is no longer being sought by the Company and to make a corresponding update to the index to exhibits. The revised version of the Exhibit supersedes in its entirety the Exhibit as originally filed with the Annual Report.

Except for the revised Exhibit and the corresponding update to the index to exhibits, this Amendment No. 2 does not amend any other information set forth in the Annual Report. This Amendment No. 2 speaks as of the filing date of the Annual Report, does not reflect any events that may have occurred subsequent to the filing date of the Annual Report, and does not modify or update in any way any disclosures made in the Annual Report. Additionally, in connection with the filing of this Amendment No. 2 and pursuant to Rule 12b-15 of the Exchange Act, the certifications of the Company’s principal executive officer and principal financial officer are also attached as exhibits hereto. This Amendment No. 2 should be read in conjunction with the Annual Report, Amendment No. 1 and our filings with the Commission subsequent to the Annual Report.

 

2


Table of Contents

PART IV

 

ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES

 

(a) LIST OF DOCUMENTS FILED AS PART OF THIS REPORT:

 

  1. Financial Statements
       The financial statements and notes thereto, and the report of the independent registered public accounting firm thereon, are set forth on pages F-1 through F-31 of the Annual Report on Form 10-K, filed with the Securities and Exchange Commission on March 27, 2012.

 

  2. Exhibits
       The exhibits listed in the accompanying index to exhibits are filed or incorporated by reference as part of this Amendment No. 2 to the Annual Report on Form 10-K/A.

 

3


Table of Contents

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

      Vermillion, Inc.
Date: May 30, 2012      

/s/ Gail S. Page

     

Gail S. Page

President and Chief Executive Officer (Principal Executive Officer)

Date: May 30, 2012      

/s/ Eric J. Schoen

     

Eric J. Schoen

Chief Accounting Officer (Principal Financial Officer)

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

 

Name

  

Title

 

Date

/s/ Gail S. Page

Gail S. Page

   President and Chief Executive Officer (Principal Executive Officer)   May 30, 2012

/s/ Eric J. Schoen

Eric J. Schoen

   Chief Accounting Officer (Principal Financial Officer)   May 30, 2012


Table of Contents

INDEX TO EXHIBITS

 

Exhibit

Number

  

Exhibit Description

   Incorporated by Reference    Filed
Herewith
      Form    File No.    Exhibit      Filing Date   
    2.1    Findings of Fact, Conclusions of Law and Order Confirming Debtor’s (Vermillion Inc.’s) Second Amended Plan of Reorganization Under Chapter 11 of the Bankruptcy Code dated January 7, 2010    8-K    000-31617      2.1       January 12, 2010   
    3.1    Fourth Amended and Restated Certificate of Incorporation of Vermillion, Inc. dated January 22, 2010    8-K    000-31617      3.1       January 25, 2010   
    3.2    Third Amended and Restated Bylaws of Vermillion, Inc.    10-K    000-34810      3.2       March 27, 2012   
    4.1    Form of Vermillion, Inc.’s (formerly Ciphergen Biosystems, Inc.) Common Stock Certificate    S-1/A    333-32812      4.1       August 24, 2000   
    4.2    Preferred Shares Rights Agreement between Vermillion, Inc. (formerly Ciphergen Biosystems, Inc.) and Continental Stock Transfer & Trust Company dated March 20, 2002    8-A    000-31617      4.2       March 21, 2002   
    4.3    Amendment to Rights Agreement between Vermillion, Inc. (formerly Ciphergen Biosystems, Inc.) and Wells Fargo Bank, N.A. dated July 22, 2005    8-K    000-31617      4.4       July 28, 2005   
    4.4    Second Amendment to Rights Agreement between Vermillion, Inc. (formerly Ciphergen Biosystems, Inc.) and Wells Fargo Bank, N.A. dated September 30, 2005    8-K    000-31617      4.5       October 4, 2005   
    4.5    Third Amendment to Rights Agreement between Vermillion, Inc. and Wells Fargo Bank, N.A., dated September 11, 2007    8-K    000-31617      10.1       September 12, 2007   
  10.1    1993 Stock Option Plan #    S-1    333-32812      10.3       March 20, 2000   
  10.2    Form of Stock Option Agreement #    S-1/A    333-32812      10.4       August 24, 2000   
  10.3    2000 Stock Plan and related form of Stock Option Agreement #    S-1/A    333-32812      10.5       August 4, 2000   
  10.4    Amended and Restated 2000 Employee Stock Purchase Plan #    10-Q    000-31617      10.6       November 14, 2007   
  10.5    Vermillion, Inc. 2010 Stock Incentive Plan #    8-K    000-31617      10.1       February 12, 2010   
  10.6    Ciphergen Biosystems, Inc. 401(k) Plan #    10-K    000-31617      10.7       March 22, 2005   


Table of Contents

Exhibit

Number

  

Exhibit Description

   Incorporated by Reference    Filed
Herewith
      Form    File No.    Exhibit      Filing Date   
  10.7    Securities Purchase Agreement by and among Vermillion, Inc. and the purchasers party thereto dated August 23, 2007    S-1    333-146354      10.57       September 27, 2007   
  10.8    Form of Warrant    10-Q    000-31617      10.51       November 14, 2007   
  10.9    Form of Securities Purchase Agreement between Vermillion, Inc. and the purchasers party thereto dated December 24, 2009    8-K    000-31617      10.1         December 29, 2009   
  10.10    Employment Agreement between Sandra A. Gardiner and Vermillion, Inc. dated April 9, 2010 #    8-K    000-31617      10.1         April 22, 2010   
  10.11    Employment Agreement between Gail S. Page and Vermillion, Inc. dated September 28, 2010 #    8-K    000-34810      10.1         September 30, 2010   
  10.12    Employment Agreement between Eric T. Fung and Vermillion, Inc. dated September 28, 2010 #    8-K    000-34810      10.2         September 30, 2010   
  10.13    Form of Severance Agreement between key executive employees and Vermillion, Inc. #    8-K    000-31617      10.1         August 29, 2008   
  10.14    Form of Proprietary Information Agreement between Vermillion, Inc. (formerly Ciphergen Biosystems, Inc.) and certain of its employees #    S-1/A    333-32812      10.9         August 24, 2000   
  10.15    Consulting Agreement between Richard G. Taylor and Vermillion, Inc. dated August 26, 2008 #    8-K    000-31617      10.1         August 29, 2008   
  10.16    MAS License Agreement with IllumeSys Pacific, Inc. dated April 7, 1997    S-1/A    333-32812      10.23       August 24, 2000   
  10.17    MAS License Agreement with Ciphergen Technologies, Inc. (formerly ISP Acquisition Corporation) dated April 7, 1997    S-1    333-32812      10.24       August 24, 2000   
  10.18    Settlement Agreement and Mutual General Release by and among Vermillion, Inc. (formerly Ciphergen Biosystems, Inc.), IllumeSys Pacific, Inc., Ciphergen Technologies, Inc., Molecular Analytical Systems, Inc., LumiCyte, Inc. and T. William Hutchens dated May 28, 2003 †    8-K    000-31617      99.2         June 11, 2003   


Table of Contents

Exhibit

Number

  

Exhibit Description

   Incorporated by Reference    Filed
Herewith
      Form    File No.    Exhibit      Filing Date   
  10.19    Assignment Agreement by and among Vermillion, Inc. (formerly Ciphergen Biosystems, Inc.), IllumeSys Pacific, Inc., Ciphergen Technologies, Inc., Molecular Analytical Systems, Inc., LumiCyte, Inc. and T. William Hutchens dated May 28, 2003 †    8-K    000-31617      99.3         June 11, 2003   
  10.20    License Agreement between Vermillion, Inc. (formerly Ciphergen Biosystems, Inc.) and Molecular Analytical Systems, Inc. dated May 28, 2003 †    8-K    000-31617      99.4         June 11, 2003   
  10.21    Collaborative Research Agreement between University College London, UCL Biomedica plc and Vermillion, Inc. (formerly Ciphergen Biosystems, Inc.) dated September 22, 2005 †    10-K    000-31617      10.54       March 17, 2006   
  10.22    Distribution and Marketing Agreement between Vermillion, Inc. (formerly Ciphergen Biosystems, Inc.) and Ciphergen Biosystems KK dated March 24, 1999    S-1/A    333-32812      10.26       September 22, 2000   
  10.23    Strategic Alliance Agreement between Vermillion, Inc. (formerly Ciphergen Biosystems, Inc.) and Quest Diagnostics Incorporated dated July 22, 2005    8-K    000-31617      10.44       July 28, 2005   
  10.24    Amendment to Strategic Alliance Agreement between Vermillion, Inc. and Quest Diagnostics Incorporated dated October 7, 2009    8-K    000-31617      10.2         October 21, 2009   
  10.25    Amendment to Strategic Alliance Agreement between Vermillion, Inc. and Quest Diagnostics Incorporated dated November 10, 2010    8-K    000-34810      10.1         November 12, 2010   
  10.26    Amendment No. 5 to Strategic Alliance Agreement by and among Vermillion, Inc. and Quest Diagnostics Incorporated and Quest Diagnostics India Private Limited, dated April 2, 2011†    10-Q    001-34810      10.1         May 10, 2011   
  10.27    Stock Purchase Agreement between Vermillion, Inc. (formerly Ciphergen Biosystems, Inc.) and Quest Diagnostics Incorporated dated July 22, 2005    8-K    000-31617      10.45       July 28, 2005   
  10.28    Warrant between Vermillion, Inc. (formerly Ciphergen Biosystems, Inc.) and Quest Diagnostics Incorporated dated July 22, 2005    8-K    000-31617      10.46       July 22, 2005   


Table of Contents

 

Exhibit

Number

  

Exhibit Description

   Incorporated by Reference    Filed
Herewith
      Form    File No.    Exhibit      Filing Date   
  10.29    Amendment to Warrant between Vermillion, Inc. (formerly Ciphergen Biosystems, Inc.) and Quest Diagnostics Incorporated dated August 29, 2007    8-K    000-31617      10.2         August 29, 2007   
  10.30    Letter Agreement between Vermillion, Inc. and Quest Diagnostics Incorporated dated August 29, 2007    S-1    333-146354      10.38       September 27, 2007   
  10.31    Credit Agreement between Vermillion, Inc. (formerly Ciphergen Biosystems, Inc.) and Quest Diagnostics Incorporated dated July 22, 2005    8-K    000-31617      10.47       July 28, 2005   
  10.32    Debtor-In-Possession Credit and Security Agreement between Vermillion, Inc. and Quest Diagnostics Incorporated dated October 7, 2009    8-K    000-31617      10.1         October 21, 2009   
  10.33    Memorialization Agreement between Vermillion, Inc. (formerly Ciphergen Biosystems, Inc.) and Quest Diagnostics Incorporated dated January 12, 2006    S-1    333-146354      10.40       September 27, 2007   
  10.34    Patent Security Agreement between Vermillion, Inc. (formerly Ciphergen Biosystems, Inc.) and Quest Diagnostics Incorporated dated July 22, 2005    8-K    000-31617      10.48       July 28, 2005   
  10.35    Asset Purchase Agreement between Vermillion, Inc. (formerly Ciphergen Biosystems, Inc.) and Bio-Rad Laboratories, Inc. dated August 14, 2006    14a    000-31617      Annex A       September 12, 2006   
  10.36    Amendment to Asset Purchase Agreement between Vermillion, Inc. (formerly Ciphergen Biosystems, Inc.) and Bio-Rad Laboratories, Inc. dated November 13, 2006    S-1    333-146354      10.47       September 27, 2007   
  10.37    Stock Purchase Agreement between Vermillion, Inc. (formerly Ciphergen Biosystems, Inc.) and Bio-Rad Laboratories, Inc. dated November 13, 2006    S-1    333-146354      10.48       September 27, 2007   
  10.38    Transition Services Agreement between Vermillion, Inc. (formerly Ciphergen Biosystems, Inc.) and Bio-Rad Laboratories, Inc. dated November 13, 2006 †    S-1/A    333-146354      10.53       November 27, 2007   


Table of Contents

Exhibit

Number

  

Exhibit Description

   Incorporated by Reference    Filed
Herewith
      Form    File No.    Exhibit      Filing Date   
  10.39    Amendment No. 1 to Transition Services Agreement between Vermillion, Inc. (formerly Ciphergen Biosystems, Inc.) and Bio-Rad Laboratories, Inc. dated May 11, 2007    S-1    333-146354      10.50       September 27, 2007   
  10.40    Amendment No. 2 to Transition Services Agreement between Vermillion, Inc. (formerly Ciphergen Biosystems, Inc.) and Bio-Rad Laboratories, Inc. dated June 15, 2007    S-1    333-146354      10.51       September 27, 2007   
  10.41    Manufacture and Supply Agreement between Vermillion, Inc. (formerly Ciphergen Biosystems, Inc.) and Bio-Rad Laboratories, Inc. dated November 13, 2006 †    S-1/A    333-146354      10.56       November 27, 2007   
  10.42    Amendment No. 1 to Manufacture and Supply Agreement between Vermillion, Inc. and Bio-Rad Laboratories, Inc. dated August 27, 2007    S-1    333-146354      10.53       September 27, 2007   
  10.43    Cross License Agreement between Vermillion, Inc. (formerly Ciphergen Biosystems, Inc.) and Bio-Rad Laboratories, Inc. dated November 13, 2006 †    S-1/A    333-146354      10.58       November 27, 2007   
  10.44    Sublicense Agreement between Vermillion, Inc. (formerly Ciphergen Biosystems, Inc.) and Bio-Rad Laboratories, Inc. dated November 13, 2006    S-1    333-146354      10.13       September 27, 2007   
  10.45    Letter Agreement between Vermillion, Inc. (formerly Ciphergen Biosystems, Inc.) and Bio-Rad Laboratories, Inc. dated November 13, 2006    S-1    333-146354      10.55       September 27, 2007   
  10.46    Sublease Agreement between Vermillion, Inc. (formerly Ciphergen Biosystems, Inc.) and Bio-Rad Laboratories, Inc. dated November 13, 2006 †    S-1/A    333-146354      10.60       November 27, 2007   
  10.47    Exclusive Distribution Agreement between Vermillion, Inc. and Pronto Diagnostics Ltd., dated August 1, 2011†    10-Q    001-34810      10.1         August 9, 2011   
  10.48    Consulting Agreement between Vermillion, Inc. and Bruce A. Huebner, dated June 17, 2011#    10-Q    001-34810      10.2         August 9, 2011   
  10.49    Consulting Agreement between Vermillion, Inc. and Eric T. Fung, dated November 4, 2011#    10-Q    001-34810      10.1         November 9, 2011   


Table of Contents

Exhibit

Number

  

Exhibit Description

   Incorporated by Reference    Filed
Herewith
 
      Form    File No.    Exhibit      Filing Date   
  10.50    Asset Purchase Agreement between Vermillion, Inc. and Correlogic Systems, Inc., dated November 8, 2011    10-K    000-34810      10.50       March 27, 2012   
  10.51    Settlement Agreement and Release between Vermillion, Inc. and Oppenheimer & Co., Inc., dated February 9, 2012    10-K    000-34810      10.51            ü   
  10.52    Employment Agreement between Vermillion, Inc. and Eric J. Schoen, dated April 4, 2012#    8-K    000-34810      10.1         April 10, 2012   
  10.53    Employment Agreement between Vermillion, Inc. and William Creech, dated April 4, 2012#    8-K    000-34810      10.2         April 10, 2012   
  14.1    Code of Ethics    8-K    001-34810      14.1         December 7, 2010   
  21.0    Subsidiaries of Registrant    10-K    001-34810      21.0         March 27, 2012   
  23.1    Consent of PricewaterhouseCoopers LLP, Independent Registered Public Accounting Firm    10-K    001-34810      23.1         March 27, 2012   
  31.1    Certification of the Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002                  ü   
  31.2    Certification of the Chief Accounting Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002                  ü   
  32.1    Certification of the Chief Executive Officer and Chief Accounting Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002                  (1
101.INS    XBRL Instance Document    10-K    001-34810      101       March 27, 2012   
101.SCH    XBRL Taxonomy Extension Schema Document    10-K    001-34810      101       March 27, 2012   
101.CAL    XBRL Taxonomy Extension Calculation Linkbase Document    10-K    001-34810      101       March 27, 2012   
101.DEF    XBRL Taxonomy Extension Definition Linkbase Document    10-K    001-34810      101       March 27, 2012   
101.LAB    XBRL Taxonomy Extension Label Linkbase Document    10-K    001-34810      101       March 27, 2012   
101.PRE    XBRL Taxonomy Extension Presentation Linkbase Document    10-K    001-34810      101       March 27, 2012   

Attached as Exhibit 101 to this report are documents formatted in XBRL (Extensible Business Reporting Language). Users of this data are advised that, pursuant to Rule 406T of Regulation S-T, the interactive data file is deemed not filed or part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, is deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is otherwise not subject to liability under these sections.

 

(1) Furnished herewith


Table of Contents
# Management contracts or compensatory plan or arrangement.
Confidential treatment has been granted with respect to certain provisions of this agreement. Omitted portions have been filed separately with the Commission.